Shares of Themis Medicare climbed 1.15% to ₹289.20 on the NSE as of 9:53 AM after the company announced its decision to merge Gujarat Themis Biosyn Limited (GTBL) with Themis Medicare Limited (TML). The proposed amalgamation aims to create a more unified and synergized entity, boosting operational efficiency and value creation.
Key Highlights of the Amalgamation:
- Amalgamation Details:
- The Boards of GTBL and TML have approved the Scheme of Amalgamation.
- The merger is subject to approvals from secured creditors, shareholders, stock exchanges, SEBI, NCLT, and other regulatory bodies.
- Share Exchange Ratio:
- For every 100 fully paid-up equity shares held in GTBL, shareholders will receive 118 equity shares of TML, based on valuations conducted by SSPA & Co. and GT Valuation Advisors Private Limited.
- Kunvarji Finstock Pvt. Ltd. provided fairness opinions for the transaction.
- Strategic Benefits:
- The merger will consolidate business operations and integrate the product value chain under one entity.
- The unified structure is expected to generate significant synergies and enhance efficiency across the organization.
- Advisors:
- Legal and tax advisory services were provided by Khaitan & Co.
This strategic consolidation is expected to streamline operations, unlock greater shareholder value, and create a stronger combined entity in the pharmaceutical and healthcare sector. Investors responded positively to the news, leading to a slight uptick in the company’s stock price.